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Introduction
Objective of off-patent pharmaceutical policies
The main policy objective of health care decision-makers is to 
maximize health gain for the population [1] by improving the allocative 
efficiency of limited resources. The objective of off-patent drug 
policies is usually defined as reduction in health expenditures without 
compromising health outcomes [2]. If clinical studies indicate equal 
outcomes between an off-patent medicine and the originator, then the 
more cost-effective medicines can be selected by Cost-minimization 
Analysis (CMA) [3]. 
Biosimilar medicines can generate savings to the society [4-6]. 
They are expected to reduce drug costs, although to a lesser degree 
than seen with small-molecule generic drugs [7]. However, health care 
policymakers should take measures to increase the use of biosimilar 
medicines [8], partly by managing concerns related to efficacy and 
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Abstract
Biosimilar medicines can generate savings to the society. However, if patient access to original biologic 
medicines is limited, the main benefit of biosimilar medicines is to treat more patients from the same health care 
budget and hence generate more health gain. 
The aim of this policy paper is to provide recommendations on how to maximise the value proposition of biosimilar 
medicines in lower income countries with more limited health care resources.
From the clinical perspective, first line use of multi-source, off-patent biologics should be considered for all 
treatment naïve patients before prescribing any other patented biologic therapies without major added benefit. 
Systematic literature reviews indicate that significant and quantifiable economic benefits from switching patients on 
maintenance biologic to biosimilars should not be sacrificed for non-quantifiable and fairly low risks of immunogenicity, 
hence a single switch of patients from an original biologic to its biosimilar alternative under medical supervision 
should be mandated after patent expiry.
From the health economic perspective authors advocate the use of cost-utility analysis to evaluate the full 
economic value of biosimilars. In sensitivity analyses decision-makers can explore the level of risk associated with 
immunogenicity, where switch of patients treated by original biologics is not the preferred policy approach anymore. 
However, authors still advocate the collection of real world pharmacovigilance data after switching patients to 
biosimilars, and reassessment of cost-effectiveness ratio after more real-world data becomes available. 
Appropriateness of biosimilar drug policies is equally important to market access of new biologic therapies in 
lower income countries. 
safety of biosimilar medicines raised by different stakeholders, including 
clinicians, patients, payers and manufacturers of originator biological 
medicines [9]. 
Interestingly the objective of biosimilar policies can be defined 
differently in countries with significant resource constraints, where 
accessibility of patients to high-cost biologic medicines is limited 
[10]. In these countries, biosimilar medicines also compete with non-
biologic therapies in case of those patients, who cannot have access to 
original biologic medicines. As health outcomes on non-biologic and 
biosimilar medicines are different, the traditionally applied CMA is not 
an appropriate methodology to understand the true economic value of 
biosimilar medicines. 
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The aim of this policy paper is to provide recommendations on how 
to maximise the value proposition of biosimilar medicines in lower 
income European countries with more limited health care resources. 
Access Restrictions in Lower Income Countries with 
Limited Resources
Launch price of innovative pharmaceuticals, including high-cost 
biologic medicines is determined according to highest acceptable price 
by payers in large size and high-income countries with the greatest 
market potential [11]. There are two reasons why these prices are usually 
not justifiable in lower income countries. At first, savings from avoided 
medical events due to improved drug therapies are less in countries with 
lower price level of medical services and lower salaries of health care 
professionals. Secondly, less affluent countries cannot afford to pay as 
much for one unit of health gain as higher income countries. 
Unfortunately, the European external price referencing system and 
the encouragement of parallel trade by several higher income European 
countries such as Germany, The Netherlands and the United Kingdom 
[12,13] prevent manufacturers of originator biologic medicines from 
reducing the list price of their high-cost products in lower income 
European countries, including Eastern Europe [14]. At Western 
European prices, new high-cost biologic medicines are usually not cost-
effective in lower income Eastern European countries. 
On the other hand, there is a strong pressure on health care 
decision makers from politicians, patient advocates, clinicians and the 
pharmaceutical industry to reimburse new biologic medicines, especially 
in key priority disease areas [15]. To respond to this political pressure 
several biologic medicines not meeting local cost-effective thresholds 
are reimbursed in lower income European countries, however various 
access restrictions are implemented to ensure the sustainability of health 
care financing [16]. These restrictions can influence prescribers, patients 
and manufacturers. 
Some of the access restrictions have major influence on health care 
providers either at individual prescriber or institutional level. In many 
countries, the prescribing practice of physicians is guided by financial 
protocols or specific guidelines which may restrict the prescription of 
biologic medicines for only a subgroup of patients compared to the 
licensed indication described by the Summary of Product Characteristics 
(SmPC). Guidelines may also allow high-priced biologics to be 
prescribed only as second line treatments, after a first line and lower 
priced non-biologic alternative failed. In other cases, treatment duration 
of biologic medicines can be restricted in financing protocols compared 
to the treatment duration specified in the SmPC, and so the medicine 
could be reimbursed only up to first couple of cycles. Payers may 
introduce volume restrictions to individual specialists or institutions 
either by capping the number of treated patients or prescribed units of 
biologic medicines. If payers narrow the list of centers who can prescribe 
high cost biologic medicines with reimbursement, some physicians 
outside those centers may seek for cheaper alternative therapies, as they 
do not want to lose their patients. 
Payers may apply various restriction techniques by influencing 
patients. Waiting lists to prevent immediate access to high-cost 
medicines are introduced even in severe diseases with rapid progression, 
such as oncology. If the disease progresses while the patient is on the 
waiting list, the therapy may not be necessary anymore. In some cases, 
the biologic therapy may be covered from a special budget with fairly 
slow, “bureaucratic” approval process for each prescription of individual 
patients. Significant co-payment associated with high priced biologic 
medicines may not only increase the cost consciousness of patients, 
but can also limit or even block the access of patients from lower 
socioeconomic classes to these medicines. Even if the medicine is fully 
reimbursed, no reimbursement or limited access to the concomitant 
molecular diagnostics or other related services may represent significant 
financial burden for poorer patients. If prescription of medicines is 
restricted to selected centers in large cities, travel time and costs for 
patients from rural areas may represent significant access barrier. 
Finally, payers may restrict the utilisation of high-cost biologic 
medicines by influencing manufacturers. Payers may delay the 
reimbursement decision with objective reasons, e.g. the reimbursement 
dossier cannot be submitted by manufacturers until at least 5 other 
European countries put the medicine to the reimbursement list. 
However, in many other cases the reason for delaying the reimbursement 
is not so objective. Price Volume Agreements (PVA) with unreasonably 
low volume of medicines may represent an efficient incentive to 
manufacturers to avoid significant payback by keeping the utilisation 
at low level. 
As a consequence of these restrictions, even if biologic medicines are 
reimbursed in several lower income countries, the real-world utilisation 
of these medicines is fairly low, as significant proportion of patients 
cannot get access to high-cost therapies. 
Value Propositions of Off-patent Biologics in Countries 
with Limited Resources 
There are three main scenarios to determine the value proposition of 
biosimilar medicines according to the status of patient access to original 
biologic medicines (Table 1). 
If the original biologic product is reimbursed without any volume 
and access restrictions, the main objective of using biosimilar medicines 
is to generate savings in health expenditures without compromising 
health outcomes. This disinvestment scenario is mainly applicable for 
higher income countries. If the original biologic product is reimbursed 
with volume and access restrictions, the main objective of biosimilar 
medicines is to treat more patients from the same health care budget, 
and hence generate more health gain (Figure 1). This special investment 
scenario is applicable for lower income EU member states and other 
middle-income countries. If the original biologic product is not 
reimbursed at all, more affordable biosimilar medicines may create an 
opportunity for public reimbursement, however, incremental budget 
is needed to generate more health gain. This investment scenario is 
applicable for low income countries [2]. 
In conclusion, in countries with restricted or no access to original 
biologic medicines the main benefit of biosimilar medicines is not 
related to their cost-saving potential, the objective of biosimilar policies 
has to be defined from an investment perspective [17-19]. The key 
question is which policy tools can facilitate the increased utilisation of 
biosimilar medicines to maximise the health gain from a given health 
care budget. These tools can be assessed from clinical and health 
economic perspectives. 
Considerations for Clinical Practice 
More extended utilisation of biosimilar medicines necessitates the 
reconsideration of current therapeutic guidelines dealing with biologic 
products. In the majority of countries generic products are first line 
treatment options in high-prevalent diseases such as hypertension, type 
2 diabetes or major depression [20-23]. Similarly, to these cases, first line 
use of biosimilar medicines should be considered for all treatment naïve 
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patients before prescribing any other patented biologic therapy, if major 
added benefit of those biologic medicines compared to biosimilar 
medicines is not proven. 
Even in some higher income countries clinical guidelines have 
changed to this direction recently, as price erosion of multi-source 
biologic medicines has become massive [24]. In Norway key opinion 
leaders envisaged first-line use of biosimilar medicines for biologic 
naïve patients in inflammatory bowel disease [25]. In Denmark, 
similar approach has been facilitated by the national council for 
expensive hospital medicines in rheumatology and gastroenterology 
[26,27]. Clinical guidelines and financial protocols should be adjusted 
accordingly in lower income countries as well. According to recent 
survey in New Zealand most physicians indicated that they would 
prescribe biosimilars for all clinical conditions in which biosimilars 
are cost-effective alternatives to biologic medicines. However, it is 
important to provide communication guidance to clinicians on how to 
explain biosimilars effectively to patients in order to reduce potential 
objections [28].
As many biologic medicines are used in chronic diseases, the 
increased utilisation of biosimilar medicines in patients who are 
currently treated with patented biologic medicines should also be 
considered. Nevertheless, switching clinically stable patients from an 
original biologic medicine to its biosimilar alternative has never been 
a straightforward decision for clinicians [8]. Additionally, debate on 
immunogenicity has been fuelled by manufacturers of original biologic 
medicines [29]. Recently, however, several systematic reviews evaluated 
the clinical consequences of switching to biosimilar medicines, but 
none of them concluded increased risk of adverse events or efficacy 
loss [30-33]. These reviews, along with evidence generated from recent 
clinical trials indicate that significant and quantifiable economic 
benefits from switching patients on maintenance biologic medicines to 
their biosimilar alternatives under medical supervision should not be 
sacrificed for non-quantifiable and fairly low risks of immunogenicity. 
This does not necessarily mean that multiple switching between 
biosimilar medicines is justifiable; however, a single switch of high 
cost original to a more affordable biosimilar medicine can be applied 
in clinical practice, especially in lower income countries with limited 
resources. 
Originator is reimbursed without access limits 
to patients
Originator is reimbursed with access limits 
to patients Originator is not reimbursed 
Value proposition Savings in drug budget
• No increase in drug budget
• Improved patient access
• Health gain
• Potential increase in drug 
budget
• Health gain
Decision Disinvestment Re-investment of savings Investment
Table 1: Value proposition of biosimilars in different access-restriction settings.
Before patent  
expiry 
After patent 
expiry 
Non-biologic  
medicine 
Biosimilar  
medicine 
Original 
biologic medicine  
4800 1200 N/A 
3800 200 2000 
1000 1000 
Equal health with 
cost-savings 
Health gain at 
additional cost 
Treatment arms 
N
um
be
r o
f p
ati
en
ts
 
Improved population health with neutral budget impact 
1000 € 3000 € 5000 € Drug price 
Re-investment 
Figure 1: Example of improving patient access with neutral budget impact by increasing utilisation of biosimilar medicines.
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Health Economic Considerations
An increasing number of countries demand evidence about 
the cost-effectiveness of biosimilars to inform pharmaceutical 
reimbursement decisions. CMA is the standard approach to prove the 
cost-effectiveness of small molecule generic medicines, as the same 
health gain is produced at lower costs. According to Simoens et al., cost-
effectiveness analysis of biosimilars is more complicated, as necessary 
evidence to obtain market authorization may not be sufficient to inform 
reimbursement decisions [3]. Consequently, CMA may not be the 
optimal approach for the economic evaluation of biosimilars in several 
different decision contexts. 
The variety of such decision problems can be categorized based 
on: 1) Previous therapy of target patient groups and 2) Selection of the 
policy relevant comparator as described in Table 2. 
Scenario 1A is relevant only in those lower income countries, where 
access to biologic medicines is restricted. For those patients who cannot 
access to original biologic medicines otherwise, affordable biosimilar 
medicines may offer extra health gain at an incremental cost. As health 
gain of the compared therapies is not equal, Cost-effectiveness Analysis 
(CEA) or its alternative, Cost-utility Analysis (CUA) has to be applied, 
in which the health gain is aggregated in Quality Adjusted Life Years 
(QALYs). 
 Scenario 2A is a relevant policy scenario in every country. Based 
on the best available evidence biosimilars offer equal health gain to 
original biologic medicines [34] and CMA indicates which medicine is 
the more cost-effective treatment option. 
Scenario 3A can be a policy relevant option in all countries, where 
decision-makers try to maximise societal benefits from biosimilar 
medicines. If there is no clear preference among different originator 
biologic medicines in the treatment guidelines, and relative effectiveness 
analyses indicate no or minimal difference between patented biologic 
alternatives, biosimilar medicines provide fairly similar health gain 
at lower costs, and therefore they should be selected before any other 
original biologic medicine. 
Scenario 1B may not be the first option to maximise societal 
benefits from biosimilar medicines. However, in those countries, where 
due to economic reasons patients could start their treatment with less 
effective non-biologic therapies, switch to biosimilar medicines may 
provide them extra health gain at incremental costs. On the other hand, 
until disease is controlled by more affordable small molecule medicines, 
switch may not be clinically relevant in several disease areas. 
Scenario 2B is a highly debated option due to the potential risk of 
immunogenicity, but still it has already been implemented in Denmark 
or Norway. Overall, the opportunity cost of not switching patients to 
biosimilar medicines is greater in lower income than higher income 
countries, as health care budgets are more limited. Current evidence 
suggests that a single switch of patients treated with original biologic to 
biosimilar products after patent expiry is not associated with increased 
risk of adverse reactions or loss of efficacy [30-33]. When there is clinical 
trial or registry based evidence about continued efficacy and non-
increased adverse event rate after switching of a biological medicine 
to its biosimilar alternative, expedited review with CMA is sufficient 
to select the most cost-effective treatment strategy. However, when 
such direct evidence is not available authors advocate the use of CEA 
or CUA to evaluate the full economic value of biosimilar medicines. 
In the sensitivity analyses of such economic evaluations decision-
makers can explore how much should be the risk of immunogenicity, 
where switch is not the preferred policy approach anymore. If that 
risk is unrealistically high, societies lose from not switching patients 
to a more affordable alternative. However, the collection of real world 
pharmacovigilance data after switching the patients to biosimilar 
medicines is still recommended and reassessment of cost-effectiveness 
is needed after more real-world data become available [34]. 
Scenario 3B may be unrealistic from the clinical point of view, 
as advanced therapy of patients with chronic diseases should not be 
changed until disease progression. 
Policy Implications
Payers have to take a strategic approach to increase societal benefit 
from biosimilar medicines [35]. Relying on free-market incentives may 
not be strong enough mainly due to hypothetical concerns related to 
the evidence base of biosimilar medicines and promotional campaigns 
organized by manufacturers of original biologic medicines. Hence, 
active government interventions instead of ‘passive disinvestment’ 
policies are needed to correct for market failures [36].
*CMA: Cost-minimization Analysis; CEA: Cost-effectiveness Analysis; CUA: Cost-utility Analysis; BIA: Budget Impact Analysis; INN: International Non-proprietary Name
**Choice of economic evaluation depends on the assumption and/or evidence on equal health gain
Table 2:  Relevance of clinical evidence and health economic methods in different scenarios.
Comparator
Non-biologics (1) Biologics with same INN (2) Other biologics with different INN (3)
New patients 
(A)
decision problem Choice of starting therapy
necessary clinical evidence
Relative effectiveness of biosimilar 
compared to non-biologics
Phase III trial result Relative effectiveness of biosimilar 
compared to biologics with different 
INN
necessary health economic 
analysis*
• CUA
• BIA
• CMA
• BIA
• CMA or CEA/CUA**
• BIA
Stable
patients on 
therapy (B)
decision problem single switch of patients on non-biologicals to biosimilar 
single switch of patients on original biologic 
to its biosimilar alternative 
not realistic clinical scenarionecessary clinical evidence
Relative effectiveness of switching to 
biosimilar compared to staying on non-
biologics
• Phase III trial results (if available)
• Risk assessment for immunogenicity 
based on literature review or existing 
clinical trial data
• (Ongoing data collection)
necessary health economic 
analysis*
• CEA/CUA
• Budget impact
• CMA (in expedited review) or CEA/CUA 
(in full review)
• Budget impact
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In lower income countries, the following policy actions are 
recommended to maximise social benefits from follow-on biologic 
medicines:
Recommendations for public administration of biosimilar 
medicines: (a) Introduction of administrative tools and policy measures 
to incentivize the choice for more affordable biosimilars. (b) Expedited 
price and reimbursement process to facilitate the timely market entry 
of biosimilars.
Recommendations for clinical guidelines: (a) Multisource 
biologic medicines should be first line biologic therapy for all patients. 
More expensive patented biologic medicines with no proven significant 
clinical benefit compared to biosimilar medicines should be only second 
line options. (b) Single switch of patients from an original biologic 
medicine to its more affordable biosimilar alternative under medical 
supervision should be mandated after patent expiry. (c) Physicians 
should not only be informed about scientific evidence on biosimilars 
but also guided on how to educate appropriately their patients on these 
medicines.
 Recommendations for evidence base of policy decisions: (a) 
CEA or CUA should be applied to judge the full economic value of 
biosimilar medicines except in those cases, when biosimilar medicines 
are compared to their original biologic alternative for treatment naïve 
patients. (b) Budget impact analysis should be used to estimate the 
savings from biosimilar medicines, if there is no patient access limit 
to biologic medicines, or the incremental budget, if patient access to 
biologic medicines is restricted. 
Recommendations for managing uncertainty: Public 
policymakers may consider different approaches to manage 
uncertainty, especially related to the switch of original biologics to 
its more affordable biosimilar version. (a) Ex-ante risk management: 
calculation of threshold for the risk of immunogenicity, where not 
switching patients to biosimilar medicines is the preferred option from 
the payers’ perspective. (b) Ex-post risk management: mandate of 
collecting pharmacovigilance data, and risk-management plan, in case 
of increased risk of immunogenicity. The risk management plan may 
even include risk-sharing agreements with manufacturers of biosimilar 
medicines. 
Conclusion
Sustainability of health care financing is challenging in all 
countries, and this is especially true for lower income economies. In 
these countries, the main policy focus is on patient access to new and 
expensive health technologies which requires appropriate biosimilar 
drug policies. However, the key success criterion of public health 
programs is how to improve the utilisation and persistence with more 
affordable medical technologies.
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